benralizumab CRSwNP
Selected indexed studies
- Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial. (J Allergy Clin Immunol, 2022) [PMID:34599979]
- Clinical efficacy and mechanisms of biologics for chronic rhinosinusitis with nasal polyps. (J Allergy Clin Immunol, 2025) [PMID:40132672]
- Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps: A Meta-Analysis of Real-World Evidence. (Allergy, 2025) [PMID:39985317]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps: A Meta-Analysis of Real-World Evidence. (2025) pubmed
- Clinical efficacy and mechanisms of biologics for chronic rhinosinusitis with nasal polyps. (2025) pubmed
- Reappraisal of Biologic Efficacy from Phase 3 Trials in Refractory Chronic Rhinosinusitis and Nasal Polyps. (2025) pubmed
- Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial. (2022) pubmed
- Efficacy of Benralizumab in Reducing FeNO in Severe Eosinophilic Asthma: The Role of CRSwNP. (2025) pubmed
- Type 2 Biomarkers for the Indication and Response to Biologics in CRSwNP. (2023) pubmed
- Biologic Therapies for Severe Asthma: Current Insights and Future Directions. (2025) pubmed
- Current Understanding of the Role of Eosinophils in CRSwNP and Implications for Treatment with Mepolizumab and Benralizumab. (2023) pubmed
- New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis. (2023) pubmed
- Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis. (2022) pubmed